English Toll-free:1-888-852-8623 or Contact Us
Keyword cannot be empty !

Factor IX / F9 Polyclonal Antibody

Cat:E-AB-60352
Manual MSDS
  • +1

Price: $ 530

Price: $ 320

Price: $ 200

Size:
200μL 120μL 60μL
Quantity:
  • Host: Rabbit
  • Reactivity: Human;Mouse;Rat
  • Applications: WB;IF
Add to cart

For research use only. Order now, ship in 3 days

Product Details
Verified Samples Verified Samples in WB:HepG2,22Rv1,HT29,HO-8910
Verified Samples in IF:Rat liver,Human placenta
Dilution

WB 1:500-1:2000, IF 1:50-1:200

Western Blot Operation Guide
Clonality Polyclonal
Immunogen Recombinant fusion protein of human Factor IX / F9 (NP_000124.1).
Abbre Factor IX / F9
Synonyms F9;F9 p22;FIX;HEMB;P19;PTC;THPH8;F9p22
Swissprot
Calculated MW 47kDa/51kDa
Observed MW 50kDa
The actual band is not consistent with the expectation.

Western blotting is a method for detecting a certain protein in a complex sample based on the specific binding of antigen and antibody. Different proteins can be divided into bands based on different mobility rates. The mobility is affected by many factors, which may cause the observed band size to be inconsistent with the expected size. The common factors include:

1. Post-translational modifications: For example, modifications such as glycosylation, phosphorylation, methylation, and acetylation will increase the molecular weight of the protein.

2. Splicing variants: Different expression patterns of various mRNA splicing bodies may produce proteins of different sizes.

3. Post-translational cleavage: Many proteins are first synthesized into precursor proteins and then cleaved to form active forms, such as COL1A1.

4. Relative charge: the composition of amino acids (the proportion of charged amino acids and uncharged amino acids).

5. Formation of multimers: For example, in protein dimer, strong interactions between proteins can cause the bands to be larger. However, the use of reducing conditions can usually avoid the formation of multimers.

If a protein in a sample has different modified forms at the same time, multiple bands may be detected on the membrane.

Cellular Localization Secreted.
Concentration 1mg/mL
Buffer PBS with 0.02% sodium azide, 50% glycerol, pH7.3.
Purification Method Affinity purification
Research Areas Cardiovascular; Immunology
Conjugation Unconjugated
Storage Store at -20°C Valid for 12 months. Avoid freeze / thaw cycles.
Shipping Ice bag
background This gene encodes vitamin K-dependent coagulation factor IX that circulates in the blood as an inactive zymogen. This factor is converted to an active form by factor XIa, which excises the activation peptide and thus generates a heavy chain and a light chain held together by one or more disulfide bonds. The role of this activated factor IX in the blood coagulation cascade is to activate factor X to its active form through interactions with Ca+2 ions, membrane phospholipids, and factor VIII. Alterations of this gene, including point mutations, insertions and deletions, cause factor IX deficiency, which is a recessive X-linked disorder, also called hemophilia B or Christmas disease. Alternative splicing results in multiple transcript variants encoding different isoforms that may undergo similar proteolytic processing.